Novartis trial suspensions seen as limited financial impact
Citi analysts said Novartis’s decision to suspend several cell-therapy clinical trials after three patient deaths is expected to have limited financial impact, pending further updates.
Novartis's decision to suspend several clinical trials for a cell therapy after three patients died is expected to have a limited financial impact, Citi analysts say in a research note.
Pending further updates, the news reduces the likelihood that the Swiss drugmaker's next-generation cell-therapy…